IDEXX Laboratories Inc
IDXX- Exchange
- Nasdaq
- Industry
- In Vitro & In Vivo Diagnostic Substances
- SEC CIK
- 0000874716
In the last 90 days, IDEXX Laboratories Inc insiders filed 0 open-market purchases and 1 sale; 1,306 institutions reported holding it in 13F filings for Q2 2026, worth $39.1B in total; 3 superinvestors hold it, including Fundsmith and Weitz Investment Management.
Q3 2022 vs. Q2 2022
How the institutions holding IDEXX Laboratories Inc changed between Q2 2022 and Q3 2022.
All holders in Q3 2022All holders in Q2 2022
| Measure | Q2 2022 | Of which not filed for Q3 2022 | Q3 2022 | Change |
|---|---|---|---|---|
| Holders | 959 | 7 | 925 | −27 |
| Shares | 73.8M | 9.29K | 73.7M | −124.5K (−0.2%) |
| Value | $25.9B | $3.26M | $24.0B | −$1.91B (−7.4%) |
7 institutions that held it in Q2 2022 haven't filed for Q3 2022 yet. Not filing isn't selling, so the changes leave them out.
New holders (59)
Institutions that held IDEXX Laboratories Inc at the end of Q3 2022 but not at the end of Q2 2022.
Sold out (86)
Institutions that held IDEXX Laboratories Inc at the end of Q2 2022 and filed for Q3 2022 without it.
Not filed for Q3 2022 yet (7)
Institutions that held IDEXX Laboratories Inc at the end of Q2 2022 and haven't filed a 13F for Q3 2022. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q2 2022 | Value, Q2 2022 |
|---|---|---|
| Brewin Dolphin Ltd | 3,916 | $1.37M |
| Advisor Partners LLC | 2,882 | $1.01M |
| Coldstream Capital Management Inc | 1,178 | $413.0K |
| Frontier Wealth Management LLC | 769 | $270.0K |
| Fieldpoint Private Securities, LLC | 357 | $125.0K |
| Private Capital Group, LLC | 135 | $47.0K |
| Brewin Dolphin Wealth Management Ltd | 55 | $19.0K |